Purchase this article with an account.
Javier Moreno; Eplerenone use to treat Central Serous Chorioretinopathy. Invest. Ophthalmol. Vis. Sci. 2014;55(13):1926.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Based on experimental data showing that Central Serous Chorioretinopathy (CSC) could result from overactivation of mineralocorticoid receptor pathway in choroid vessels, eplerenone, a mineralocorticoid receptor antagonist, was studied as a potential treatment for CSC.
Three patients diagnosed of unilateral CSC were treated with eplerenone 25 mgrs/day. All three patients did not received any previous treatment, all of them had an onset of symptoms for more than three months. Prior to treatment, Visual Acuity (VA) was taken (Snellen chart), Optical Coherence Tomography (OCT, Cirrus Humphrey-Zeiss) of the macular area, was performed also, evaluating the height of the subretinal fluid at the fovea, and the total volumen at the macular cube. The evaluation was repeated at one month, two months and three months after treatment.
There was an improve in VA in all three patients since the first month after initiating treatment and it was related with a decrease in the subretinal fluid, measured with OCT, with less height at the subfoveal space and a decrease in total volume measured through macular cube.
Eplerenone seems to be an alternative to treat CSC with good results. It could be interesting to prove this treatment in a ramdomized controlled trial with more cases.
This PDF is available to Subscribers Only